Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nilotinib - Georgetown University/ KeifeRx

X
Drug Profile

Nilotinib - Georgetown University/ KeifeRx

Alternative Names: KFRX-01; Nilotinib BE

Latest Information Update: 28 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgetown University
  • Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Imidazoles; Ketones; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Discoidin domain receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Lewy body disease; Parkinson's disease
  • No development reported Huntington's disease

Most Recent Events

  • 28 Feb 2023 No recent reports of development identified for phase-I development in Huntington's-disease(In the elderly, In adults) in USA (PO)
  • 09 Dec 2021 Georgetown University completes a phase II trial in Parkinson's disease (In the elderly, In adults) in USA (PO) (NCT02954978)
  • 08 Dec 2021 KeifeRx plans a phase III NILEAD trial for Alzheimer's disease (Early-stage disease) (PO, Capsule) in early 2022 (NCT05143528)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top